HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aprotinin in lung transplantation is associated with an increased incidence of primary graft dysfunction.

AbstractOBJECTIVE:
Aprotinin has been widely used to reduce bleeding and transfusion requirements in cardiac surgery and in lung transplantation. A recent study found a significant reduction in severe (grade III) primary graft dysfunction (PGD) in lung transplantation where aprotinin had been used. However, recently, concerns regarding the safety of aprotinin have been raised, and the future use of aprotinin is uncertain. In our institution, aprotinin has been widely used in cardiac surgery and transplantation. We decided to review our lung transplant caseload to investigate the impact of aprotinin on PGD and mortality and to guide our future clinical use of this antifibrinolytic.
METHODS:
A retrospective review of prospectively collected data on 213 consecutive patients who underwent single- or double-lung transplantation was performed. Ninety-nine patients, who received aprotinin, were compared with 114 patients who did not. The main outcome variables analysed were development of primary graft dysfunction, renal impairment and mortality.
RESULTS:
Aprotinin was associated with a significantly increased risk of PGD in the first 48 h postoperatively (p=0.01).
CONCLUSIONS:
In conclusion, although the benefits of aprotinin on blood loss are well established, this study does not provide support for the use of aprotinin to reduce PGD in lung transplantation and indicates that aprotinin may in fact have a detrimental effect.
AuthorsSilvana F Marasco, David Pilcher, Takahiro Oto, Wenly Chang, Anne Griffiths, Vince Pellegrino, Justin Chan, Michael Bailey
JournalEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (Eur J Cardiothorac Surg) Vol. 37 Issue 2 Pg. 420-5 (Feb 2010) ISSN: 1873-734X [Electronic] Germany
PMID19767212 (Publication Type: Journal Article)
CopyrightCrown Copyright 2009. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Hemostatics
  • Serine Proteinase Inhibitors
  • Aprotinin
  • Creatinine
Topics
  • Adult
  • Aprotinin (adverse effects)
  • Creatinine (blood)
  • Epidemiologic Methods
  • Female
  • Hemostasis, Surgical (adverse effects, methods)
  • Hemostatics (adverse effects)
  • Humans
  • Kidney (physiopathology)
  • Lung Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Primary Graft Dysfunction (chemically induced, physiopathology)
  • Serine Proteinase Inhibitors (adverse effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: